Commentary

Video

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

Author(s):

Vijayakrishna Gadi, MD, University of Illinois College of MedicineMegan Kruse, MD, of Cleveland Clinic

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Related Videos
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Arya Mariam Roy, MBBS
Suneel Kamath, MD
Julia Foldi, MD, PhD
Suneel Kamath, MD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
VK Gadi, MD, PhD
Related Content
Karthik V. Giridhar, MD
June 12th 2024

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Erika Hamilton, MD, of Sarah Cannon Research Institute
June 5th 2024

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

Lydia Pace, MD, MPH
June 5th 2024

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer